Relationship between systemic Lupus Erythematosus Erythematosus activity and socioeconomic status in patients in the Lupus-Py 2.0 Cohort
Abstract
Introduction: Systemic Lupus Erythematosus is a chronic multisystemic disease prevalent in women of childbearing age. Its evolution depends on factors such as socioeconomic status, which may influence adherence to treatment. This study, in the absence of nationwide data, analyzes whether there is a relationship between socioeconomic status and disease activity.
Objective: To evaluate the association between the level of Systemic Lupus Erythematosus Erythematosus activity and the average socioeconomic level in patients of the Rheumatolo- gy Department of the Hospital de Clínicas.
Materials and methods: Observational, analytical and cross-sectional study in patients with Systemic Lupus Erythematosus in a third level center. Epidemiological variables (age, sex, origin) and clinical variables (phenotypes: cutaneous, articular, hematological, renal, among others) were recorded. Activity was assessed with the SLEDAI 2K and socioecono- mic level with the Graffar Scale.
Results: 119 patients were included, 93.3% women, mean age 34.7 ± 13.6 years. Mean SLEDAI 2K was 8.6 ± 7 points. The majority presented a medium (30.3 %) and medium-low (38.7 %) socioeconomic level. No association was found between socioeconomic level and disease activity.
Conclusion: In the Lupus Paraguay 2.0 cohort there was no association between socioeco- nomic level and disease activity. It is recommended to replicate the study with cohorts from other centers to obtain more representative data at national level.
Downloads
References
(1) Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 21 de Abr de 2016;165(3):551-65.
(2) Uramoto KM, Michet Jr. CJ, Thumboo J, Sunku J, O’Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum [Internet]. 1 de enero de 1999;42(1):46-50. Disponibleen: https://doi.org/10.1002/1529-0131(199901)42:1<46::AID-ANR6> 3.0.CO
(3) Duarte-García A, Hocaoglu M, Valenzuela-Almada M, Osei-Onomah SA, Dabit JY, Sanchez-Rodriguez A, et al. Rising incidence and prevalence of systemic lupus erythematosus: A population-based study over four decades. Ann Rheum Dis. 1 de septiembre de 2022;81(9):1260-6.
(4) Parodis I, Lanata C, Nikolopoulos D, Blazer A, Yazdany J. Reframing health disparities in SLE: A critical reassessment of racial and ethnic differences in lupus disease outcomes. Best Pract Res Clin Rheumatol. 2023;37:101741
(5) Fernández M, Alarcón GS, Calvo-alén J, Andrade R, McGwin Jr. G, Vilá LM, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Care Res (Hoboken) [Internet]. 15 de mayo de 2007;57(4):576-84. Disponible en: https://doi.org/10.1002/art.22672
(6) Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcõn GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum. mar 2013;65(3):753-63.
(7) Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-91.
(8) Bauce GJ, Córdova MA. Revista del Instituto Nacional de Higiene «Rafael Rangel» Cuestionario socioeconómico aplicado a grupos familiares del Distrito Capital para investigaciones relacionadas con la salud pública. 2010.
(9) Barber MRW, Clarke AE. Socioeconomic consequences of systemic lupus erythematosus. Vol. 29, Current Opinion in Rheumatology. Lippincott Williams and Wilkins; 2017. p. 480-5.
(10) Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Vol. 14, Expert Review of Clinical Immunology. Taylor and Francis Ltd; 2018. p. 1043-53.
(11) Pimentel-Quiroz VR, Ugarte-Gil MF, Pons-Estel GJ, Soriano ER, Saurit V, Sato EI, et al. Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Semin Arthritis Rheum. 1 de oct 2017;47(2):199-203.
(12) Quintana R, Silvestre AMR, Goñi M, García V, Mathern N, Jorfen M, et al. Prevalence of musculoskeletal disorders and rheumatic diseases in the indigenous Qom population of Rosario, Argentina. Clin Rheumatol. 1 de jul 2016; 35:5-14.
(13) González LA, Toloza SM, McGwin G, Alarcón GS. Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. Lupus. 2013;22(12):1214-24.
(14) Senna E. Prevalence of Rheymatic Diseases in Brazil: A Study Using the COPCORD Approach. J Rheumatol. Ago 2004;31.
(15) Leong PY, Huang JY, Chiou JY, Bai YC, Wei JCC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population- based study. Sci Rep. 1 de dic 2021;11(1).
(16) Etchegaray-Morales I, Mendoza-Pinto C, Arellano-Avendaño FJ, Ibañez-Ovando S, Munguía-Realpozo P, Orbe-Sosa JG, et al. Epidemiology of systemic lupus erythematosus in Latin America. Reumatología Clinica. Ediciones Doyma, S.L.; 2024.
(17) Fatoye F, Gebrye T, Mbada C. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. Vol. 42, Rheumatology International. Springer Science and Business Media Deutschland GmbH; 2022. p. 2097-107.
(18) Scolnik M, Marin J, Valeiras SM, Marchese MF, Talani AS, Avellaneda NL, et al. Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. Lupus Sci Med [Internet]. 2014;1:21.
(19) George A, Wong-Pak A, Peschken CA, Silverman E, Pineau C, Smith CD, et al. Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. Arthritis Care Res (Hoboken). 1 de ene 2017;69(1):124-32.
(20) Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update in the diagnosis and management of systemic lupus erythematosus. Vol. 80, Annals of the Rheumatic Diseases. BMJ Publishing Group; 2021. p. 14-25.
(21) Pamuk ON, Akbay FG, Dönmez S, Yilmaz N, Calayir GB, Yavuz S. The clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: Report from two centers. Lupus. nov 2013;22(13):1416-24.
(22) Al Arfaj AS, Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus. 2009;18(5):465-73.
(23) Carter EE, Barr SG, Clarke AE. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. Vol. 12, Nature Reviews Rheumatology. Nature Publishing Group; 2016. p. 605-20.
(24) Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, et al. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus. 15 de octubre de 2022;
(25) Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Vol. 17, Nature Reviews Rheumatology. Nature Research; 2021. p. 515-32.
(26) Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients with Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity among «Hispanics». Medicine. ene 2004;83(1):1-17.
(27) Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Vol. 32, Best Practice and Research: Clinical Rheumatology. Bailliere Tindall Ltd; 2018. p. 188-205.
(28) Karina Guerra-Sáenz E, Gustavo Narváez-Navarro Á, Cecilia Hernández-López A, Bello Saucedo J, Ruiz-Cantú G, Cordero-Pérez P, et al. Actitud hacia la donación y el trasplante de órganos y tejidos de tres instituciones de salud. Gaceta Médica de México Artículo Original. Correspondencia [Internet]. Vol. 152. 2016. Disponible en: www.anmm.org.mx
(29) Alarcón GS, Calvo-Alén J, McGwin G, Uribe AG, Toloza SMA, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis. sept 2006;65(9):1168-74.
(30) Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: Trends over time and major contributors. Rheumatology (United Kingdom). 1 de dic 2020;59:V29-38.
(31) Hasan B, Fike A, Hasni S. Health disparities in systemic lupus erythematosus - a narrative review. Vol. 41, Clinical Rheumatology. Springer Science and Business Media Deutschland GmbH; 2022. p. 3299-311.
(32) Williams JN, Drenkard C, Lim SS. The impact of social determinants of health on the presentation, management and outcomes of systemic lupus erythematosus. Rheumatology (United Kingdom). 1 de abr 2023;62:I10-4.
Copyright (c) 2024 Santiago Ferreira Maidana, Laura Martínez, Paola Pusineri, Astrid Paats, Isabel Acosta Colmán
This work is licensed under a Creative Commons Attribution 4.0 International License.
